Rakovina Therapeutics Announces Second Upsizing of Private Placement

VANCOUVER, British Columbia, July 19, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (the “Company”), a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies, is pleased to announce, further to the press releases dated May 23, 2024 and June 20, 2024, that to accommodate additional indications of interest it will upsize the previously announced private placement of $2.0 million to $2.3 million, subject to TSX Venture Exchange (TSX-V) approval. The terms of the private placement otherwise remain unchanged. The Company now anticipates closing the private placement on or about July 22, 2024. Read More